R. Tony Tripeny
R. Tony Tripeny's purchase track record
How the stock did after each of R. Tony Tripeny's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2026 | MLAB | $102K | pending | pending | — |
| 3/27/2026 | IPX | $99K | +14.5% | -15.3% | +21.6% |
| 3/10/2026 | MLAB | $100K | +49.1% | +69.2% | +13.2% |
| 8/9/2022 | MLAB | $100K | -12.1% | -4.0% | +1.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
IPX Gets Analyst Coverage, Second U.S. Army Task Order for Titanium. IperionX received a second task order from the U.S. Army focused on accelerating industrial-scale American titanium production, marking continued government engagement with the company's manufacturing capabilities. Separately, Jefferies initiated analyst coverage of the stock with a $26 price target, bringing more institutional attention to the company. The analyst consensus price target across six firms stands at $45.50, with individual targets ranging from $26 to $55. These developments signal growing both government and institutional interest in IperionX's domestic titanium production operations.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Corning Faces Rating Downgrade Amid AI Risk Concerns. A recent Seeking Alpha report downgraded Corning, arguing the stock carries significant risk relative to its current valuation in the AI sector. This negative sentiment contrasts with other recent coverage highlighting Corning's new long-term deals in life sciences and its role in the growing cell culture market. The mixed narrative reflects a market weighing the company's strong fundamental partnerships against concerns about its high price-to-earnings ratio.
Transaction History
| MLAB | ▲ Buy | Option Exercise | 2,784 | $0 | 8/15/2026 | View on chart |
| MLAB | ▲ Buy | Open Market | 900 | $102K | 8/13/2026 | View on chart |
| IPX | ▲ Buy | Open Market | 4,187 | $99K | 3/27/2026 | View on chart |
| MLAB | ▲ Buy | Open Market | 1,315 | $100K | 3/10/2026 | View on chart |
| MLAB | ▲ Buy | Option Exercise | 1,404 | $0 | 8/15/2025 | View on chart |
| MLAB | ▲ Buy | Option Exercise | 1,074 | $0 | 9/1/2024 | View on chart |
| MLAB | ▲ Buy | Option Exercise | 1,105 | $0 | 8/15/2023 | View on chart |
| MLAB | ▲ Buy | Open Market | 500 | $100K | 8/9/2022 | View on chart |
| GLW | ▲ Buy | Option Exercise | 959 | $34K | 5/2/2022 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 5,015 | $180K | 5/2/2022 | View on chart |
| GLW | ▲ Buy | Option Exercise | 8,862 | $319K | 5/2/2022 | View on chart |
| GLW | ▲ Buy | Option Exercise | 16,393 | $0 | 4/18/2022 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 7,984 | $270K | 4/18/2022 | View on chart |
| GLW | ▲ Buy | Option Exercise | 486 | — | 2/2/2022 | View on chart |
| GLW | ▲ Buy | Option Exercise | 1,030 | — | 2/2/2022 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 1,516 | $65K | 2/2/2022 | View on chart |
| GLW | ▼ Sell | Tax Withholding | 874 | $33K | 1/7/2022 | View on chart |
| GLW | ▲ Buy | Option Exercise | 874 | $0 | 1/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
MLAB Declares Quarterly Dividend
MLAB announced it will pay a quarterly dividend, adding a new source of income for shareholders. The dividend yield is 0.70%, which is modest compared to the company's high valuation. The move comes as the stock trades near its 12‑month support level of $99.48.
MLAB Declares Quarterly Dividend. MLAB announced it will pay a quarterly dividend, adding a new source of income for shareholders. The dividend yield is 0.70%, which is modest compared to the company's high valuation. The move comes as the stock trades near its 12‑month support level of $99.48.